Saturday 17 October 2026 Export PHAR’s income statement to Excel — free account

Pharming Group N.V. Sponsored ADR

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.36 0.27 −2.80%

Follow PHAR

Alert me

Market cap: $681.6M
P/E: 62.4×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 5/9
Altman Z: 3.88
Beneish M: −2.78
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 681.61

Revenue 366.49

Net Income 15.84

Free Cash Flow 34.37

Net Debt (60.41)

Current Ratio 3.01

Debt/Equity 0.36

P/E ratio 62.40

Fwd P/E 0.00

P/S ratio 1.36

P/B ratio 1.85

Past 5Y EPS Growth (41.42%)

This Y EPS Growth 486.06%

Next Y EPS Growth (10.10%)

Next Y revenue growth 1,956.11%

Next 5Y EPS Growth 109.28%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 22.42%

10-year low 10-year high

P/S against its own 10 years 0.07%

10-year low 10-year high

P/B against its own 10 years 0.57%

10-year low 10-year high

EV/Sales against its own 10 years 0.64%

10-year low 10-year high

EV/FCF against its own 10 years 6.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	213	168	180	158
Receivables	46	55	55	57
Inventory	57	56	65	65
Other	—	—	—	—
	316	278	299	281

	2023	2024	2025	Q'26
Payables	73	67	106	82
ST’ Debt	2	4	5	5
Other	—	—	1	2
	78	74	116	93

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.13%	22.30%
Cash Flow	—	(8.14%)	34.55%
Earnings	—	(40.35%)	(40.70%)
Book Value	—	8.60%	10.63%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	72	90	—	—	—
’25	79	93	97	107	376
’24	56	74	75	93	297
’23	43	55	67	81	245
’22	47	49	54	57	206
’21	44	49	52	52	199
’20	54	44	54	63	212

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	(10)	—	—	—
’25	0	12	32	11	55
’24	(8)	(13)	10	9	(2)
’23	(23)	(10)	4	12	(17)
’22	1	4	17	5	22
’21	7	9	3	15	38
’20	22	23	65	20	84

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	(10)	—	—	—
’25	0	12	32	10	54
’24	(8)	(13)	9	9	(3)
’23	(23)	(10)	3	11	(19)
’22	0	3	16	5	20
’21	4	5	(6)	15	21
’20	15	23	63	17	68

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.07)	0.03	—	—	—
’25	(0.22)	0.06	0.10	0.07	0.04
’24	(0.19)	(0.02)	(0.02)	0.05	(0.16)
’23	(0.17)	(0.02)	0.05	(0.04)	(0.15)
’22	0.05	0.02	0.13	(0.02)	0.19
’21	0.13	0.01	0.00	0.00	0.19
’20	0.13	0.01	0.01	0.01	0.58

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	14.08	7.58	6.10	9.65	6.65	7.50	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	21.99	15.52	13.63	17.81	13.20	18.30
People
People	Employees	—	—	—	258	229	277	332	382	404	409
	Revenue/emp, $m	0.00	0.00	0.00	0.73	0.93	0.72	0.62	0.64	0.74	0.92
Income, $m
Income, $m	Revenue	17	108	155	189	212	199	206	245	297	376
	Gross margin, %	65.73	82.38	80.81	87.37	88.91	89.37	91.46	89.72	88.09	87.90
	EBT	(18)	(103)	1	52	44	23	15	(12)	(8)	13
	EBT margin, %	(110.48)	(95.61)	0.63	27.62	20.78	11.60	7.29	(4.90)	(2.86)	3.42
	Net income	(18)	0	29	52	44	23	15	(12)	(8)	13
	Depreciation	1	4	5	6	8	20	13	16	16	11
Per share, $
Per share, $	Revenue	0.04	0.22	2.53	3.02	3.33	3.10	3.17	3.73	4.43	5.46
	Earnings	(0.04)	(0.18)	0.05	0.65	0.58	0.21	0.21	(0.15)	(0.16)	0.04
	Cash flow	(0.03)	0.07	0.55	1.19	1.31	0.59	0.35	(0.26)	(0.03)	0.79
	Capex	0.00	0.00	0.00	(0.41)	(0.24)	(0.26)	(0.03)	(0.02)	(0.01)	(0.01)
	Free cash flow	(0.03)	0.07	0.55	0.78	1.07	0.33	0.32	(0.29)	(0.04)	0.78
	Book value	0.07	0.04	1.16	1.87	2.88	3.00	3.15	3.33	3.29	4.02
	Shares, m	415	500	61	63	64	64	65	66	67	69
Valuation, ×
Valuation, ×	P/E	80.75	80.75	80.75	80.75	77.31	63.00	60.74	0.00	0.00	441.75
	P/S	52.19	52.19	52.19	52.19	44.99	29.41	3.65	3.08	2.27	3.24
	P/B	66.90	66.90	66.90	66.90	52.65	30.09	3.69	3.45	3.06	4.39
	EV/Sales	52.01	52.01	52.01	52.01	44.79	29.25	3.29	2.77	1.99	3.02
	EV/FCF	57.70	57.70	57.70	57.70	79.60	312.97	45.55	(34.00)	(184.03)	21.04
Cash, $m
Cash, $m	Operating cash flow	(11)	37	34	74	84	38	22	(17)	(2)	55
	Capex	(2)	(7)	(4)	(25)	(15)	(17)	(2)	(1)	(1)	(1)
	Free cash flow	(11)	37	34	49	68	21	20	(19)	(3)	54
Balance, $m
Balance, $m	Working capital	11	33	38	5	186	203	218	238	205	184
	Total debt	71	99	84	56	152	141	133	138	82	98
	Net debt	37	28	(8)	(18)	(54)	(51)	(74)	(75)	(85)	(82)
	Shareholders’ equity	29	19	71	117	183	193	205	219	221	277
Returns, %
Returns, %	ROA	(11.06)	(137.67)	15.12	16.14	11.20	3.92	3.32	(2.37)	(2.74)	0.63
	ROIC	0.00	0.00	0.00	43.09	36.93	5.98	8.73	(2.34)	(3.97)	8.27
	ROE	(76.40)	(380.21)	63.57	43.08	25.11	8.50	6.88	(4.98)	(5.38)	1.14

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OABI OmniAb, Inc.	$687.7M	— (loss-making)	— (loss-making)	+244.24% (above 0%: growing)	n/m	+211.16% (above 0%: growing)	95.45%	(49.47%)	Compare
ANNX Annexon, Inc.	$682.5M	— (loss-making)	—	—	n/m	−26.41% (below 0%: shrinking)	0.00%	0.00%	Compare
MDXG MiMedx Group, Inc	$682.2M	111×	— (loss-making)	−34.73% (below 0%: shrinking)	n/m	−174.83% (below 0%: shrinking)	68.96%	(28.69%)	Compare
CADL Candel Therapeutics, Inc.	$681.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−93.35% (below 0%: shrinking)	0.00%	0.00%	Compare
PHAR Pharming Group N.V. Sponsored ADR	$681.6M	62.4×	— (loss-making)	−3.22% (below 0%: shrinking)	−57.14% (below 0%: shrinking)	−183.87% (below 0%: shrinking)	83.92%	1.44%
GYRE Gyre Therapeutics, Inc.	$678.6M	— (loss-making)	— (loss-making)	−2.12% (below 0%: shrinking)	n/m	−130.45% (below 0%: shrinking)	92.41%	(49.35%)	Compare
AURA Aura Biosciences, Inc.	$657.5M	— (loss-making)	—	—	n/m	−56.26% (below 0%: shrinking)	0.00%	0.00%	Compare
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
PRME Prime Medicine, Inc.	$654.8M	— (loss-making)	— (loss-making)	+3.50% (above 0%: growing)	n/m	+4.40% (above 0%: growing)	100.00%	(3,750.87%)	Compare
Median of peers	$680.2M	—	—	0.00%	—	−41.33%	34.48%	(14.34%)

All 614 Biotechnology stocks →

Pharming Group N.V. Sponsored ADR (PHAR) key facts

Strength: Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024.
Pharming Group N.V. Sponsored ADR (PHAR) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, PHAR traded at $9.36, a market capitalization of $681.6 million.
Return on equity was 1.14% and debt-to-equity 0.36.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.88 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.